Ticagrelor, a more potent P2Y12 inhibitor, has been shown to reduce major adverse cardiac events (MACE) in acute coronary syndromes (ACS). It is increasingly used as a first line therapy in ACS. However, more potent P2Y12 inhibition has been associated with increased bleeding. This may be of particular concern for patients with ACS who require coronary artery bypass surgery (CABG). In particular, the timing for cessation of ticagrelor before proceeding to CABG is unclear. RAPID TITRATE CABG is a randomized vanguard study to evaluate the feasibility and preliminary safety of a strategy of early versus delayed CABG in ACS patients initially treated with ticagrelor and to identify potential mechanisms underlying benefits or complications of early bypass surgery.

Inclusion Criteria:

• ACS patient referred for CABG and have received >= 1 dose of ticagrelor before decision for CABG made

Exclusion Criteria:

Patients are excluded if they:

• refuse consent for enrollment
• are deemed to require immediate CABG (Day 0 or day 1)
• have a ST-elevation myocardial infarction (STEMI )initially treated with primary PCI
• are undergoing concurrent valve surgery
• are intolerant or allergic to aspirin
• have been on an oral anticoagulant (including a vitamin K antagonist or a NOAC)
• received adjuvant therapy with a glycoprotein IIbIIIa inhibitor
• have a co-morbidity with life-expectancy of < 1 year
• have active bleeding